A Multi Center, Open Label Study of the Human Anti TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Crohn's Disease.

Trial Profile

A Multi Center, Open Label Study of the Human Anti TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Crohn's Disease.

Completed
Phase of Trial: Phase III

Latest Information Update: 22 Jun 2013

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Crohn's disease
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ADHERE
  • Sponsors Abbott Laboratories
  • Most Recent Events

    • 31 Oct 2012 Planned number of patients added (960) as reported by European Clinical Trials Database record.
    • 11 Jul 2011 Additional trial locations added as reported by ClinicalTrials.gov.
    • 01 Oct 2010 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top